HDAC4 and breast carcinoma: Given that the expression level of SerRS also showed slight decrease in breast cancer (Fig. 1m), the application of HDAC4/5 inhibitors combined with small molecules that increase SerRS expression, such as all-trans retinoic acid and emodin,43,44 could achieve promising effects in the therapy of breast cancers.